These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28898876)

  • 1. Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS).
    Serebruany VL; Cherepanov V; Kim MH; Litvinov O; Cabrera-Fuentes HA; Marciniak TA
    Cardiology; 2017; 138(4):249-253. PubMed ID: 28898876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    Fahmy AI; Mekkawy MA; Abou-Ali A
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):175-181. PubMed ID: 30738497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
    Serebruany VL; Dinicolantonio JJ; Can MM; Pershukov IV; Kuliczkowski W
    Cardiology; 2013; 126(1):35-40. PubMed ID: 23860246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases.
    Hagiwara H; Fukuta H; Niimura T; Zamami Y; Ishizawa K; Kimura K; Kamiya T; Ohte N
    Int J Med Sci; 2020; 17(6):728-733. PubMed ID: 32218694
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.
    Kim HK; Jeong MH; Lim KS; Kim JH; Lim HC; Kim MC; Hong YJ; Kim SS; Park KH; Chang KS
    Int J Cardiol; 2017 Aug; 240():326-331. PubMed ID: 28487152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching From Ticagrelor or Prasugrel to Clopidogrel.
    Nawarskas JJ; Montoya TN
    Cardiol Rev; 2018; 26(2):107-111. PubMed ID: 29215418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
    Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System.
    Cherepanov V; Fortmann SD; Hyun Kim M; Marciniak TA; Litvinov O; Mihalev K; Serebruany VL
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):69-71. PubMed ID: 29272379
    [No Abstract]   [Full Text] [Related]  

  • 19. Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting.
    Serebruany VL; Tomek A; Kim MH; Litvinov O; Marciniak TA
    TH Open; 2017 Jul; 1(2):e101-e105. PubMed ID: 31249915
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
    Bednar F; Kroupa J; Ondrakova M; Osmancik P; Kopa M; Motovska Z
    J Thromb Thrombolysis; 2016 May; 41(4):549-55. PubMed ID: 26340851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.